deltatrials
Unknown PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05124028

A Study of Orelabrutinib in Patients With ITP

A Study of Orelabrutinib in Patients With Primary Immune Thrombocytopenia (ITP)

Sponsor: Peking University People's Hospital

Conditions Immune Thrombocytopenia
Interventions Orelabrutinib
Updated 4 times since 2021 Last updated: Nov 6, 2021 Started: Dec 1, 2021 Primary completion: Mar 1, 2022 Completion: Jun 1, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Immune Thrombocytopenia, this trial is ongoing. The trial is conducted by Peking University People's Hospital and has accumulated 4 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Dec 2021 – ~Dec 2023 · 24 months · monthly snapshotNot Yet Recruiting~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

4 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE1/PHASE2

    Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Dec 2023 — Jul 2024 [monthly]

    Unknown Status PHASE1_PHASE2

    Status: Not Yet Recruiting → Unknown Status

  4. Dec 2021 — Dec 2023 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Peking University People's Hospital
Data source: Peking University People's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations